Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared
“Our R&D efforts continue to provide support for the value of our novel
formulation technology platform for not only patients and providers, but
for payers and healthcare systems as well,” said
Xeris will present the first data from its Phase 2 study of RTU,
room-temperature stable liquid glucagon for congenital hyperinsulinemia
The full data will be shared during an oral presentation scheduled for
AMCP: “A Ready-To-Use Liquid Glucagon Rescue Pen for Severe Hypoglycemia Demonstrates Reduced Healthcare Payer Costs in a Budget Impact Model.” (Abstract E11, Published in JMCP Supplement)
Results of a Xeris budget impact model on the estimated potential
reduction in costs associated with use of its RTU room-temperature
stable liquid glucagon will be presented in a poster during the Academy
of Managed Care Pharmacy’s AMCP Managed Care & Specialty Pharmacy Annual
A New Drug Application (NDA) for Xeris’ lead product candidate, Gvoke
HypoPen™ for the treatment of severe hypoglycemia, is currently under
review with the
Omnipod® is a registered trademark of
About Congenital Hyperinsulinism (CHI)
CHI is a very rare genetic disorder that affects 1 in 25,000 to 50,000 babies. It causes insulin cells of the pancreas, called beta cells, to secrete too much insulin. Excess insulin causes low plasma sugar (hypoglycemia). Common symptoms include irritability, sleepiness, lethargy, excessive hunger, and rapid heart rate. CHI can cause persistent hypoglycemia in newborn babies and children. Hypoglycemia can be very dangerous because the brain needs a constant source of sugar. If the brain doesn't get the sugar it needs, prolonged and extremely low blood sugar (severe hypoglycemia) can lead to seizures, coma, brain damage, and possibly death.
Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keep blood glucose at the right level in healthy individuals. In people with diabetes who are dependent on insulin, this control system is disrupted, and insulin must be injected to avoid high levels of blood glucose (hyperglycemia). The opposite effect, or low blood glucose (hypoglycemia), is also prevalent in this population due to dysregulated glucagon secretion. Severe hypoglycemia is a serious condition and can lead to seizures, coma, potential brain injury and, if untreated, death.
Glucagon is the standard of care for treating severe hypoglycemia.
According to the
Xeris is a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use, room-temperature stable injectable and infusible drug formulations. The Company’s proprietary XeriSol™ and XeriJect™ formulation technologies are being evaluated for the subcutaneous (SC) and intramuscular (IM) delivery of highly-concentrated, non-aqueous, ready-to-use formulations of peptides, small molecules, proteins, and antibodies using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. XeriSol™ and XeriJect™ have the potential to offer distinct advantages over existing formulations of marketed and development-stage products, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. These attributes may lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system. Further information about Xeris can be found at www.xerispharma.com.
Any statements in this press release about future expectations, plans
and prospects for
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Xeris Investor Contact
Senior Vice President, Investor Relations and Corporate Communications